ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cohort Study"

  • Abstract Number: 0576 • ACR Convergence 2023

    Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers

    Andrew Concoff1, Vasileios Kyttaris2, Vaneet Sandhu3, Tyler O'Malley4, Giorgio Casaburi4, Sudha Kumar4, Chau Ching Liu5, Susan Manzi6 and Joeseph Ahearn5, 1Exagen, Los Angeles, CA, 2BIDMC, Boston, MA, 3Loma Linda University, Loma Linda, CA, 4Exagen, Vista, CA, 5Allegheny Health Network, Pittsburgh, PA, 6Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease, affecting multiple organ systems with varying severity among patients. SLE presents a diagnostic challenge…
  • Abstract Number: 1109 • ACR Convergence 2023

    Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

    Blanka Stiburkova1, Katerina Pavelcova2, Jana Masinova1, Marketa Pavlikova3 and Karel Pavelka4, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Praha 2, Czech Republic, 3Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic

    Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
  • Abstract Number: 1642 • ACR Convergence 2023

    Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort

    Paras Karmacharya1, Daniel W. Byrne2, Alisa Stephens-Shields3, Leslie Crofford4, M. Elaine Husni5, Jose Scher6, Ethan Craig3, Robert Fitzsimmons3, Soumya Reddy7, Marina Nighat Magrey8, Jessica A Walsh9 and Alexis R Ogdie3, 1Vanderbilt University, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Pennsylvania, Philadelphia, PA, 4Vanderbilt University Medical Center, Melbourne, AR, 5Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, 6New York University School of Medicine, New York, NY, 7NYU School of Medicine, New York, NY, 8Case Western Reserve University, University Hospitals, Cleveland, OH, 9Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT

    Background/Purpose: Despite an increasing number of therapeutic options, less than one-third of patients with PsA achieve remission. A major cause of non-response is that PsA…
  • Abstract Number: 2351 • ACR Convergence 2023

    Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years

    Yan Chen1, Karen Worley2, Brendan Rabideau1, Bernard Rubin3, Benson Wu1, Rose Chang1 and Maral DerSarkissian1, 1Analysis Group, Boston, MA, 2GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, 3GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC

    Background/Purpose: BEL efficacy in pts with SLE has been previously demonstrated in clinical and real-world studies.1 However, there are limited data on differences in outcomes…
  • Abstract Number: 0273 • ACR Convergence 2023

    Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement

    Guy Katz1, Liam Harvey2, Yasmin Hernandez-Barco1, Ana Fernandes1, Grace McMahon1, Isha Jha1, Zachary Wallace3, Cory Perugino1 and John Stone4, 1Massachusetts General Hospital, Boston, MA, 2Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, 3Massachusetts General Hospital, Newton, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory disease that can affect nearly every organ system. Autoimmune pancreatitis (AIP) is among the most common…
  • Abstract Number: 0634 • ACR Convergence 2023

    Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study

    Raychel Barallon1, Gene-Siew Ngian1, Diane Apostolopoulos1, Dylan Hansen2, Kathleen Morrisroe3, Wendy Stevens4, Susanna Proudman5, Mandana Nikpour6 and Joanne Sahhar1, 1Monash Health and Monash University, Clayton, Australia, 2Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, 3The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, 4Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, 5Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, 6The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…
  • Abstract Number: 1119 • ACR Convergence 2023

    Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice

    Silvia Sirotti1, Joao Madruga-Dias2, Antonella Adinolfi3, Garifallia Sakellariou4, Davide Rozza5, Greta Carrara5, Gianpiero Landolfi5, Carlo Alberto Scire5, Annamaria Iagnocco6 and Georgios Filippou1, 1IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, 2Centro Hospitalar do Médio Tejo, NOVA Medical School, Lisbon, Portugal, 3Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, 4Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, 5Società Italiana di Reumatologia, Epidemiology Research Unit, Milan, Italy, 6University of Turin, Roma, Italy

    Background/Purpose: The RADIAL study is aimed to evaluate the performance of a composite approach, based on clinical, laboratory and ultrasound (US) data in the differential…
  • Abstract Number: 1675 • ACR Convergence 2023

    Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors

    Maria Suarez-Almazor1, Juan Ruiz2, Xiudong Lei2, Chi-Fang Wu2, Hui Zhao2, Suja Rajan3, Heather Lin2 and Sharon Giordano2, 1MD Anderson Cancer Center, Houston, TX, 2The University of Texas, MD Anderson Cancer Center, Houston, TX, 3University of Texas School of Public Health, Houston, TX

    Background/Purpose: There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and concomitant cancer. Few studies…
  • Abstract Number: 2377 • ACR Convergence 2023

    The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis

    Sebastian Sattui1, Xiaoqing Fu2, Claire Cook2, Shruthi Srivatsan2, Yuqing Zhang2 and Zachary Wallace3, 1University of Pittsburgh, Pittsburgh, PA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: Older adults with ANCA-associated vasculitis (AAV) have distinct clinical presentations and outcomes when compared to younger adults. Despite a high incidence of AAV in…
  • Abstract Number: 0330 • ACR Convergence 2023

    Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement

    Liam Harvey1, Guy Katz2, Yasmin Hernandez-Barco2, Ana Fernandes2, Aubree McMahon2, Grace McMahon2, Isha Jha2, Zachary Wallace3, Cory Perugino2 and John Stone4, 1Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Newton, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: IgG4-Related Disease (IgG4-RD) is a systemic immune-mediated disease that commonly involves the pancreas in the form of autoimmune pancreatitis (AIP). Despite being one of…
  • Abstract Number: 0646 • ACR Convergence 2023

    Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity

    Kamini Kuchinad1, Ji Soo Kim1, Adrianne Woods1, Gwen Leatherman1, Laura Gutierrez2, Maureen Mayes3, Robyn Domsic4, Paula Ramos5, Richard Silver5, John Varga6, Lesley Ann Saketkoo7, Suzanne Kafaja8, Victoria Shanmugam9, Jessica Gordon10, Lorinda Chung11, Elana Bernstein12, Pravitt Gourh13, Francesco Boin14, Daniel Kastner15, Scott Zeger16, Livia Casciola-Rosen1, Fred Wigley1 and Ami Shah17, 1Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, 2Johns Hopkins Medicine, Baltimore, MD, 3Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 4University of Pittsburgh, Pittsburgh, PA, 5Medical University of South Carolina, Charleston, SC, 6University of Michigan, Ann Arbor, MI, 7University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 8UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, 9Victoria Shanmugam, MD, Great Falls, VA, 10Hospital for Special Surgery, New York, NY, 11Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 12Columbia University, New York, NY, 13National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 14Cedars-Sinai Medical Center, Los Angeles, CA, 15National Human Genome Research Institute, Bethesda, MD, 16Johns Hopkins University, Baltimore, MD, 17Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD

    Background/Purpose: Individuals with self-identified Black race have a higher incidence of systemic sclerosis (SSc), develop SSc at a younger age, and have a more severe…
  • Abstract Number: 1129 • ACR Convergence 2023

    Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study

    Saeyun Lee1, Sujin Kim2, Suzanne Segerstrom2, Polly Ferguson1 and Aleksander Lenert3, 1University of Iowa Carver College of Medicine, Iowa City, IA, 2University of Kentucky, Lexington, KY, 3University of Iowa, Iowa City, IA

    Background/Purpose: Autoinflammatory syndromes (AIS), a group of rare rheumatic diseases driven by the innate immune system, remain understudied due to the lack of prospective cohorts.…
  • Abstract Number: 1914 • ACR Convergence 2023

    Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes

    Cristina Corrales Selaya1, David Martínez-Lopez2, Diana Prieto-Peña1, Fabricio Benavides1, Jose Luis Martin-Varillas3 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3Hospital de Laredo, Laredo, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
  • Abstract Number: 2454 • ACR Convergence 2023

    Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study

    Zhiyong Chen1, Shiow-Ing Wang2, James Cheng-Chung Wei3 and Sheng-Ming Dai1, 1Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan, 3Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan

    Background/Purpose: Patients with endometriosis have a variety of autoimmune abnormalities. Our objective was to investigate the risk of incident antiphospholipid syndrome (APS) in patients with…
  • Abstract Number: 0365 • ACR Convergence 2023

    Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges

    Stacey Tarvin1, Amy Rakestraw2, Jessica Lee2, N. Shaun Matthews3, Susan H. Ballinger2 and Christina M. Sparks2, 1Riley Hospital for Children at Indiana University Health, Indianapolis, IN, 2Indiana University School of Medicine, Indianapolis, IN, 3Indiana University School of Dentistry, Indianapolis, IN

    Background/Purpose: Temporomandibular joint (TMJ) arthritis, a condition frequently overlooked in patients with JIA, can result in joint damage if not promptly treated. Such damage presents…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology